Daewoong Co., Ltd. (KRX:003090)
17,990
+510 (2.92%)
Aug 28, 2026, 3:30 PM KST
Daewoong Revenue
Daewoong had revenue of 570.82B KRW in the quarter ending June 30, 2026, with 8.02% growth. This brings the company's revenue in the last twelve months to 2.12T, up 4.55% year-over-year. In the year 2025, Daewoong had annual revenue of 2.07T with 6.79% growth.
Revenue (ttm)
2.12T
Revenue Growth
+4.55%
P/S Ratio
0.36
Revenue / Employee
5.08B
Employees
418
Market Cap
756.24B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.07T | 131.45B | 6.79% |
| Dec 31, 2024 | 1.94T | 123.08B | 6.79% |
| Dec 31, 2023 | 1.81T | 116.50B | 6.86% |
| Dec 31, 2022 | 1.70T | 185.96B | 12.30% |
| Dec 31, 2021 | 1.51T | 156.04B | 11.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Biopharma | 2.04T |
| Chong Kun Dang Pharmaceutical | 1.74T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.06T |
| Dong-A ST | 860.94B |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |
Daewoong News
- 2 months ago - Arcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle East - Financial Post
- 7 months ago - AEON Biopharma Completes BPD Type 2a Meeting With FDA - Nasdaq